{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:41:16Z","timestamp":1793425276311,"version":"4.5.0"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T00:00:00Z","timestamp":1517788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0192353","type":"journal-article","created":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T18:33:59Z","timestamp":1517855639000},"page":"e0192353","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Hexons from adenovirus serotypes 5 and 48 differentially protect adenovirus vectors from neutralization by mouse and human serum"],"prefix":"10.1371","volume":"13","author":[{"given":"Andrew W.","family":"Harmon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rituparna","family":"Moitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhili","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1135-2629","authenticated-orcid":true,"given":"Andrew P.","family":"Byrnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,2,5]]},"reference":[{"key":"ref1","unstructured":"The Journal of Gene Medicine Gene Therapy Clinical Trials Worldwide 2017. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.wiley.com\/legacy\/wileychi\/genmed\/clinical\/\" xlink:type=\"simple\">http:\/\/www.wiley.com\/legacy\/wileychi\/genmed\/clinical\/<\/ext-link>."},{"key":"ref2","first-page":"37","article-title":"Safety and efficacy of gene-based therapeutics for inherited disorders","author":"AW Harmon","year":"2017"},{"issue":"4","key":"ref3","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/mt.2008.307","article-title":"Redundant and synergistic mechanisms control the sequestration of blood-born adenovirus in the liver","volume":"17","author":"NC Di Paolo","year":"2009","journal-title":"Mol Ther"},{"key":"ref4","first-page":"1","article-title":"The importance of coagulation factors binding to adenovirus: historical perspectives and implications for gene delivery","author":"E Lopez-Gordo","year":"2014","journal-title":"Expert Opin Drug Deliv"},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2008.01.016","article-title":"Adenovirus serotype 5 hexon mediates liver gene transfer","volume":"132","author":"SN Waddington","year":"2008","journal-title":"Cell"},{"issue":"14","key":"ref6","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1073\/pnas.0711757105","article-title":"Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo","volume":"105","author":"O Kalyuzhniy","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"ref7","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/mt.2008.132","article-title":"Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver","volume":"16","author":"F Vigant","year":"2008","journal-title":"Mol Ther"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/gt.2011.87","article-title":"Coagulation factor X mediates adenovirus type 5 liver gene transfer in non-human primates (<italic>Microcebus murinus<\/italic>)","volume":"19","author":"R Alba","year":"2012","journal-title":"Gene Ther"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1128\/JVI.01939-15","article-title":"Hepatocyte heparan sulfate is required for adeno-associated virus 2 but dispensable for adenovirus 5 liver transduction in vivo","volume":"90","author":"AK Zaiss","year":"2015","journal-title":"J Virol"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nm.3107","article-title":"Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement","volume":"19","author":"Z Xu","year":"2013","journal-title":"Nat Med"},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.it.2004.02.004","article-title":"Polyreactivity of antibody molecules","volume":"25","author":"AL Notkins","year":"2004","journal-title":"Trends Immunol"},{"issue":"4","key":"ref12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jaut.2007.07.015","article-title":"Properties and function of polyreactive antibodies and polyreactive antigen-binding B cells","volume":"29","author":"ZH Zhou","year":"2007","journal-title":"J Autoimmun"},{"key":"ref13","first-page":"167","article-title":"Structure and function of natural antibodies","volume":"210","author":"P Casali","year":"1996","journal-title":"Curr Top Microbiol Immunol"},{"issue":"5447","key":"ref14","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1126\/science.286.5447.2156","article-title":"Control of early viral and bacterial distribution and disease by natural antibodies","volume":"286","author":"AF Ochsenbein","year":"1999","journal-title":"Science"},{"issue":"23","key":"ref15","doi-asserted-by":"crossref","first-page":"11705","DOI":"10.1128\/JVI.01320-08","article-title":"Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement","volume":"82","author":"ZL Xu","year":"2008","journal-title":"J Virol"},{"issue":"7","key":"ref16","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1128\/JVI.01392-12","article-title":"Circulating antibodies and macrophages as modulators of adenovirus pharmacology","volume":"87","author":"R Khare","year":"2013","journal-title":"J Virol"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"e85432","DOI":"10.1371\/journal.pone.0085432","article-title":"Innate functions of immunoglobulin M lessen liver gene transfer with helper-dependent adenovirus","volume":"9","author":"C Unzu","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"ref18","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1128\/JVI.03217-14","article-title":"Impact of natural IgM concentration on gene therapy with adenovirus type 5 vectors","volume":"89","author":"Q Qiu","year":"2015","journal-title":"J Virol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0065-2776(08)60340-5","article-title":"The classical complement pathway: activation and regulation of the first complement component","volume":"37","author":"NR Cooper","year":"1985","journal-title":"Adv Immunol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0167-5699(86)90168-4","article-title":"Immunoglobulin flexibility in complement activation","volume":"7","author":"A Feinstein","year":"1986","journal-title":"Immunol Today"},{"issue":"35","key":"ref21","doi-asserted-by":"crossref","first-page":"14960","DOI":"10.1073\/pnas.0903805106","article-title":"The human IgM pentamer is a mushroom-shaped molecule with a flexural bias","volume":"106","author":"DM Czajkowsky","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"ref22","doi-asserted-by":"crossref","first-page":"e1004673","DOI":"10.1371\/journal.ppat.1004673","article-title":"Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo","volume":"11","author":"J Ma","year":"2015","journal-title":"PLoS Pathog"},{"key":"ref23","first-page":"367","article-title":"Adenovirus vectors for gene therapy","author":"AP Byrnes","year":"2016"},{"issue":"50","key":"ref24","doi-asserted-by":"crossref","first-page":"17361","DOI":"10.1021\/bi981177x","article-title":"Coagulation factor X-binding protein from <italic>Deinagkistrodon acutus<\/italic> venom is a Gla domain-binding protein","volume":"37","author":"H Atoda","year":"1998","journal-title":"Biochemistry"},{"issue":"7090","key":"ref25","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature04721","article-title":"Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity","volume":"441","author":"DM Roberts","year":"2006","journal-title":"Nature"},{"issue":"7","key":"ref26","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/gt.2016.32","article-title":"The relevance of coagulation factor X protection of adenoviruses in human sera","volume":"23","author":"MR Duffy","year":"2016","journal-title":"Gene Ther"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/BF01541346","article-title":"Half-life of polyreactive antibodies","volume":"14","author":"G Sigounas","year":"1994","journal-title":"J Clin Immunol"},{"issue":"4","key":"ref28","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.4049\/jimmunol.126.4.1562","article-title":"Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum","volume":"126","author":"DP Beebe","year":"1981","journal-title":"J Immunol"},{"issue":"46","key":"ref29","doi-asserted-by":"crossref","first-page":"19985","DOI":"10.1073\/pnas.1014074107","article-title":"Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21)","volume":"107","author":"DL Mallery","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1\u20132","key":"ref30","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jim.2009.11.003","article-title":"Preparing serum for functional complement assays","volume":"352","author":"PJ Lachmann","year":"2010","journal-title":"J Immunol Methods"},{"issue":"4","key":"ref31","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1128\/JVI.05760-11","article-title":"Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors","volume":"86","author":"R Khare","year":"2012","journal-title":"J Virol"},{"issue":"32","key":"ref32","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"DH Barouch","year":"2011","journal-title":"Vaccine"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1128\/JVI.06254-11","article-title":"Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection","volume":"86","author":"RR Bradley","year":"2012","journal-title":"J Virol"},{"issue":"2","key":"ref34","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1128\/JVI.06165-11","article-title":"Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions","volume":"86","author":"RR Bradley","year":"2012","journal-title":"J Virol"},{"issue":"9","key":"ref35","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1089\/hum.2011.003","article-title":"Systemic delivery of a novel liver-detargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model","volume":"22","author":"Z Zhang","year":"2011","journal-title":"Hum Gene Ther"},{"issue":"12","key":"ref36","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1038\/mt.2012.162","article-title":"Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery","volume":"20","author":"L Coughlan","year":"2012","journal-title":"Mol Ther"},{"issue":"8","key":"ref37","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1128\/CVI.00207-14","article-title":"Hexon hypervariable region-modified adenovirus type 5 (Ad5) vectors display reduced hepatotoxicity but induce T lymphocyte phenotypes similar to Ad5 vectors","volume":"21","author":"JE Teigler","year":"2014","journal-title":"Clin Vaccine Immunol"},{"issue":"8","key":"ref38","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/mt.2014.80","article-title":"Ad5\/48 hexon oncolytic virus expressing sTGFbetaRIIFc produces reduced hepatic and systemic toxicities and inhibits prostate cancer bone metastases","volume":"22","author":"W Xu","year":"2014","journal-title":"Mol Ther"},{"issue":"3","key":"ref39","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/v8030078","article-title":"A novel vaccine approach for Chagas disease using rare adenovirus serotype 48 vectors","volume":"8","author":"AL Farrow","year":"2016","journal-title":"Viruses"},{"issue":"7","key":"ref40","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1093\/infdis\/jiu217","article-title":"First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002)","volume":"210","author":"LR Baden","year":"2014","journal-title":"J Infect Dis"},{"issue":"23","key":"ref41","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1038\/sj.gt.3301611","article-title":"Complement activation by recombinant adenoviruses","volume":"8","author":"G Cichon","year":"2001","journal-title":"Gene Ther"},{"issue":"4","key":"ref42","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/gt.2014.2","article-title":"Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood","volume":"21","author":"Y Di","year":"2014","journal-title":"Gene Ther"},{"issue":"9","key":"ref43","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1182\/blood-2008-09-178459","article-title":"Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1","volume":"113","author":"RC Carlisle","year":"2009","journal-title":"Blood"},{"issue":"1","key":"ref44","doi-asserted-by":"crossref","first-page":"e1000277","DOI":"10.1371\/journal.ppat.1000277","article-title":"The cell adhesion molecule &quot;CAR&quot; and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution","volume":"5","author":"E Seiradake","year":"2009","journal-title":"PLoS Pathog"},{"issue":"1\u20132","key":"ref45","first-page":"155","article-title":"Strength evaluation of transcriptional regulatory elements for transgene expression by adenovirus vector","volume":"81","author":"ZL Xu","year":"2002","journal-title":"J Control Release"},{"issue":"17","key":"ref46","doi-asserted-by":"crossref","first-page":"9661","DOI":"10.1128\/JVI.00462-13","article-title":"Identification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors","volume":"87","author":"JT Bruder","year":"2013","journal-title":"J Virol"},{"issue":"5","key":"ref47","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/0092-8674(92)90030-G","article-title":"RAG-1-deficient mice have no mature B and T lymphocytes","volume":"68","author":"P Mombaerts","year":"1992","journal-title":"Cell"},{"key":"ref48","first-page":"187","article-title":"Natural antibodies: methods and protocols. Methods in Molecular Biology","volume":"1643","author":"Z Xu","year":"2017"},{"issue":"17","key":"ref49","doi-asserted-by":"crossref","first-page":"9610","DOI":"10.1128\/JVI.01070-13","article-title":"Coagulation factor binding orientation and dimerization may influence infectivity of adenovirus-coagulation factor complexes","volume":"87","author":"EE Irons","year":"2013","journal-title":"J Virol"},{"key":"ref50","first-page":"1","article-title":"Encyclopedia of research design","author":"H Abdi","year":"2010"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0192353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T21:30:03Z","timestamp":1693517403000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0192353"}},"subtitle":[],"editor":[{"given":"Ilya","family":"Ulasov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,2,5]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,2,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0192353","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,5]]}}}